A single-arm, open-label trial study of THX-RS01 in treating Tourette syndrome

Trial Profile

A single-arm, open-label trial study of THX-RS01 in treating Tourette syndrome

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 09 Apr 2018

At a glance

  • Drugs Dronabinol/palmitoylethanolamide (Primary)
  • Indications Gilles de la Tourette's syndrome
  • Focus Proof of concept; Therapeutic Use
  • Most Recent Events

    • 09 Apr 2018 According to Therapix Biosciences Ltd. media release, based on the data from this trial the company is planning to start another trial (see profile 700284724) in adult Tourette syndrome patients.
    • 09 Apr 2018 Complete results from this study will be presented at the 2018 European Society for the Study of Tourette syndrome meeting, as reported in a Therapix Biosciences media release.
    • 09 Apr 2018 According to Therapix Biosciences Ltd. media release, twelve of the 16 subjects elected to continue into a 24-week extension phase of the trial, which is nearing completion.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top